61272-71-7

Usage

Uses

Used in Organic Synthesis:
5-BROMO-1H-INDAZOL-3-AMINE is used as an organic synthesis intermediate for the creation of various complex organic molecules. Its unique structure allows for further functionalization and modification, making it a valuable building block in the synthesis of advanced organic compounds.
Used in Pharmaceutical Industry:
5-BROMO-1H-INDAZOL-3-AMINE is used as a pharmaceutical intermediate, playing a crucial role in the development of new drugs and therapeutic agents. Its chemical properties enable it to be incorporated into the structures of potential pharmaceutical compounds, contributing to their overall efficacy and function.
Used in Laboratory Research and Development:
5-BROMO-1H-INDAZOL-3-AMINE is utilized in laboratory research and development processes, where it serves as a key component in the exploration of new chemical reactions and the synthesis of novel compounds. Its presence in the lab allows researchers to study its reactivity and potential applications in various chemical and biological contexts.
Used in Chemical Production Process:
In the chemical production process, 5-BROMO-1H-INDAZOL-3-AMINE is employed as an intermediate to produce a range of chemical products. Its versatility and reactivity make it a valuable asset in the manufacturing of various chemicals, contributing to the overall efficiency and effectiveness of the production process.

Synthesis

Hydrazine hydrate (18 mL) was added to Example 62C (1.93 g, 6.94 mmol.) in ethanol (10 mL). The mixture was heated to 95°C. overnight. The mixture was diluted with ethyl acetate and washed with water. Some of the product precipitated in the separatory funnel and was filtered to afford the title compound. The ethyl acetate layer was concentrated under reduced pressure and the resulting solid was triturated with methanol. 5-bromo-1H-indazol-3-amine. The title compound was prepared according to the procedure outlined in Example 62D substituting 5-bromo-2-fluorobenzonitrile for Example 62C. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.55 (s, 1H), 7.92 (d, J=1.87 Hz, 1H), 7.30 (dd, J=8.79, 1.89 Hz, 1H), 7.19 (d, J=8.78 Hz, 1H), 5.41 (s, 2H).

InChI:InChI=1/C7H6BrN3/c8-4-1-2-6-5(3-4)7(9)11-10-6/h1-3H,(H3,9,10,11)

Upstream product

• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 
• 39263-32-6 2-amino-5-bromobenzonitrile 

Downstream Products

• 1036380-75-2 3-amino-5-bromobenzo[b]thiophene-2-carboxylic acid methyl ester 
• 1432912-73-6 tert-butyl 3-[bis(tert-butoxycarbonyl)amino]-5-(5-chloro-2-{4-[(2,4-dimethoxybenzyl)-(1,2,4-thiadiazol-5-yl)sulfamoyl]-2,5-difluorophenoxy}phenyl)-1H-indazole-1-carboxylate 
• 1432912-66-7 tert-butyl 3-[bis(tert-butoxycarbonyl)amino]-5-(5-chloro-2-hydroxyphenyl)-1H-indazole-1-carboxylate 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.

Fragment-based discovery of JAK-2 inhibitors

Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor.

5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS

Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

Thiazole compounds and methods of use

The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

GLUCOKINASE ACTIVATORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of wherein the variables are as defined herein.

KINASE INHIBITORS

A compound having the general structure of Formula (I) or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

3-Aminoindazole derivatives

.Iadd.Pharmaceutical compositions having muscle relaxant and analgesic activity containing 3-aminoindazoles..Iaddend.